Orphagen discovers and develops small molecules at drug targets that have significant unrealized potential in areas of high clinical need. We focus on the unexplored or “orphan” members of the nuclear receptor family, the source of many successful drugs.

Orphagen has been primarily supported by non-dilutive funding, from grants, contracts and partnership milestones.